| Steven C Howe, MD | |
|
1717 Oak Park Blvd, Second Floor, Lake Charles, LA 70601-8991 | |
| (337) 494-6799 | |
| (337) 430-6950 |
| Full Name | Steven C Howe |
|---|---|
| Gender | Male |
| Speciality | Cardiac Surgery |
| Experience | 32 Years |
| Location | 1717 Oak Park Blvd, Lake Charles, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497702740 | NPI | - | NPPES |
| P00340517 | Other | LA | RAILROAD MEDICARE |
| 1397262 | Other | LA | AETNA |
| 1712906 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | MD.200879 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Loma Linda University Medical Center-murrieta | Murrieta, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of California | 3577476761 | 1692 |
News Archive
A recent study conducted at the United States Department of Energy's (DOE) Brookhaven National Laboratory provides the first atomic-level detailed model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope protein when bound to human proteins within the lungs. The study was recently published in Nature Communications.
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Halo Healthcare, Inc. announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO diagnostic device for breast cancer risk assessment.
› Verified 7 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376646869 PECOS PAC ID: 3577476761 Enrollment ID: O20031112000695 |
News Archive
A recent study conducted at the United States Department of Energy's (DOE) Brookhaven National Laboratory provides the first atomic-level detailed model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope protein when bound to human proteins within the lungs. The study was recently published in Nature Communications.
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Halo Healthcare, Inc. announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO diagnostic device for breast cancer risk assessment.
› Verified 7 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235232778 PECOS PAC ID: 3577476761 Enrollment ID: O20040920001143 |
News Archive
A recent study conducted at the United States Department of Energy's (DOE) Brookhaven National Laboratory provides the first atomic-level detailed model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope protein when bound to human proteins within the lungs. The study was recently published in Nature Communications.
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Halo Healthcare, Inc. announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO diagnostic device for breast cancer risk assessment.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven C Howe, MD 1717 Oak Park Blvd, Second Floor, Lake Charles, LA 70601-8991 Ph: (337) 494-6799 | Steven C Howe, MD 1717 Oak Park Blvd, Second Floor, Lake Charles, LA 70601-8991 Ph: (337) 494-6799 |
News Archive
A recent study conducted at the United States Department of Energy's (DOE) Brookhaven National Laboratory provides the first atomic-level detailed model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope protein when bound to human proteins within the lungs. The study was recently published in Nature Communications.
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Halo Healthcare, Inc. announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO diagnostic device for breast cancer risk assessment.
› Verified 7 days ago
Daniel Lincoln Beckles, M.D., PHD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 401 Dr Michael Debakey Dr, Lake Charles, LA 70601 Phone: 337-513-0100 Fax: 337-513-0105 | |
Joseph Gregory Lugo, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1717 Oak Park Blvd Fl 2, Lake Charles, LA 70601 Phone: 337-494-6799 Fax: 337-430-6950 |